ArticleFrontiers in oncology2026
Case Report: Giant undifferentiated pleomorphic sarcoma of the breast combined with contralateral high-grade intraductal carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reports an exceptionally rare case of a 43-year-old female presenting with concurrent giant pleomorphic undifferentiated sarcoma and high-grade intraductal carcinoma of the contralateral breast. The tumor, remarkably large and comparable in size to a basketball, presented significant diagnostic and therapeutic challenges. Following a multidisciplinary consultation, the patient underwent a comprehensive treatment regimen, which included left mastectomy, modified radical mastectomy, vacuum-assisted closure (VSD) negative pressure drainage, radiotherapy, and endocrine therapy for the high-grade intraductal carcinoma. Post-treatment follow-up over a period of 2 to 5 years revealed a satisfactory recovery with no evidence of recurrence or metastasis. This case underscores the critical role of a multidisciplinary approach in managing rare and complex breast malignancies and highlights the potential for favorable outcomes even in cases involving exceptionally large tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.